We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Joint Advisory Committee Backs Janssen’s NDA for Treatment-Resistant Depression
Joint Advisory Committee Backs Janssen’s NDA for Treatment-Resistant Depression
A joint FDA advisory committee voted in favor of the safety, efficacy and risk-benefit profile of Janssen’s NDA for treatment of treatment-resistant depression.